Ventures Fund Iv General Pa... Net Worth

The estimated Net Worth of Ventures Fund Iv General Pa... is at least 219 千$ dollars as of 19 March 2021. Ventures Pa owns over 210,000 units of Rubius Therapeutics Inc stock worth over 218,597$ and over the last 4 years Ventures sold RUBY stock worth over 0$.

Ventures Pa RUBY stock SEC Form 4 insiders trading

Ventures has made over 1 trades of the Rubius Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently Ventures bought 210,000 units of RUBY stock worth 6,090,000$ on 19 March 2021.

The largest trade Ventures's ever made was buying 210,000 units of Rubius Therapeutics Inc stock on 19 March 2021 worth over 6,090,000$. On average, Ventures trades about 210,000 units every 0 days since 2021. As of 19 March 2021 Ventures still owns at least 2,633,703 units of Rubius Therapeutics Inc stock.

You can see the complete history of Ventures Pa stock trades at the bottom of the page.

Insiders trading at Rubius Therapeutics Inc

Over the last 6 years, insiders at Rubius Therapeutics Inc have traded over 2,165,279$ worth of Rubius Therapeutics Inc stock and bought 305,000 units worth 6,624,680$ . The most active insiders traders include Noubar Afeyan、Roger Pomerantz、Robert Langer. On average, Rubius Therapeutics Inc executives and independent directors trade stock every 51 days with the average trade being worth of 2,709$. The most recent stock trade was executed by Dannielle Appelhans on 24 February 2023, trading 10,385 units of RUBY stock currently worth 1,350$.

What does Rubius Therapeutics Inc do?

developing a novel enucleated cell (ecell)(tm) therapy platform for unmet medical needs. founded by flagship venturelabs.

Complete history of Ventures Pa stock trades at Rubius Therapeutics Inc

Rubius Therapeutics Inc executives and stock owners

Rubius Therapeutics Inc executives and other stock owners filed with the SEC include:

• Pablo Cagnoni,
  President, Chief Executive Officer, Director
• Maiken Keson-Brookes,
  Chief Legal Officer, Corporate Secretary
• Dr. Pablo J. Cagnoni M.D., Ph.D.,
  CEO, Pres & Director
• David Epstein,
  Chairman of the Board
• Laurence A. Turka M.D.,
  Chief Scientific Officer and Head of Research & Translational Medicine
• Natalie Holles,
  Independent Director
• David R. Epstein B.Sc., M.B.A.,
  Exec. Chairman
• Dannielle Appelhans,
  Chief Operating Officer
• Anne Prener,
  Independent Director
• Jonathan Symonds,
  Independent Director
• Francis Cuss,
  Independent Director
• Catherine Sohn,
  Independent Director
• Noubar Afeyan,
  Independent Director
• Michael Rosenblatt,
  Independent Director
• Lori Melancon,
  IR Contact Officer
• Christina Coughlin,
  Chief Medical Officer
• Greg ..,
  Chief Quality Officer
• Laurence Turka,
  Chief Scientific Officer
• Kris Elverum,
  Senior Vice President - Business Development and Strategy
• Jose Carmona,
  Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
• Jill Murray,
  VP & Head of HR
• Marissa Hanify,
  Director of Corp. Communications
• Maiken Keson-Brookes,
  Chief Legal Officer & Corp. Sec.
• Elhan Webb C.F.A.,
  VP of Investor Relations
• Mark J. Hernon,
  Chief Information Officer
• Spencer Fisk,
  Sr. VP & Chief Technical Operations Officer
• Jose I. Carmona,
  CFO, Principal Accounting Officer & Treasurer
• Ventures Fund Iv General Pa...,
  
• Susanne Schaffert,
  Director
• Robert Langer,
  Director
• Roger Pomerantz,
  Director
• Ventures Fund Iv General Pa...,
  
• Torben Straight Nissen,
  President
• Christopher L. Carpenter,
  Chief Medical Officer
• Dannielle Appelhans,
  CEO and President